Navigation Links
Clinical Data Reported on Vidaza in Hematologic Malignancies and,Advanced Solid Tumors

quarterly report on Form 10-Q for the fiscal quarter ended March 30, 2007 and other filings with the Securities and Exchange Commission. Exelixis expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

SOURCE Exelixis, Inc.

Investor Contact: Charles Butler, Director, Corporate Communications,

+1-650-837-7277, cbutler@exelixis.com, or

Media Contact: Hal Mackins, Corporate Communications,

+1-650-837-7012, hmackins@exelixis.com, both of Exelixis, Inc.

Web site: http://www.exelixis.com <http://www.exelixis.com/>

-------------

(Back to top)

Exelixis Reports Integrated Data From Phase II Clinical Trials of XL999 at ASCO

CHICAGO, June 3, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Exelixis, Inc. (Nasdaq: EXEL) reported integrated data from six Phase II clinical trials of XL999 in patients with non-small cell lung cancer (NSCLC), renal cell carcinoma, metastatic colorectal cancer, recurrent ovarian cancer, acute myelogenous leukemia (AML), and multiple myeloma. Results show preliminary anti-tumor activity in patients with NSCLC and AML, as well as a cardiovascular adverse event profile consistent with previously reported data. The data were presented in a poster session on Sunday, June 3, 2007 (Abstract #3591) at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO).

The primary objectives of each trial were to determine the response rate and to further evaluate the safety and tolerabilit
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
(Date:12/14/2009)... 14 Sword Diagnostics, Inc. is pleased ... (USPTO) has issued patent number 7,599,057 titled ... using Raman Scattering" to the company. The patent ... sensitivity. ,, "The issuance of this patent ... with our continued development and commercialization," said Dave ...
(Date:12/14/2009)... DIEGO, Dec. 14 Cardium Therapeutics (NYSE ... "Phase 2b Study of GAM501 (Ad5PDGF-B/Collagen) in the ... Wound Healing: Science and Industry Conference held December ... The conference is attended by top industry ... advanced wound healing. Dr. Barbara K. Sosnowski, ...
(Date:12/14/2009)... Authentidate Holding Corp. (Nasdaq: ... Health Information Exchange and workflow management services, ... Carolinas ("HCC"), a home health agency, and ... equipment supplier, have selected Authentidate,s Inscrybe® Healthcare ... for the completion of patient care orders. ...
Breaking Medicine Technology:Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development 2Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development 3Cardium Presents at Tenth Annual Wound Healing: Science and Industry Conference on Matrix Wound Healing Clinical Development 4Home Care of the Carolinas and Alliance Medical, Inc. Select Authentidate's Inscrybe Healthcare to Improve Care Order Processing 2Home Care of the Carolinas and Alliance Medical, Inc. Select Authentidate's Inscrybe Healthcare to Improve Care Order Processing 3Home Care of the Carolinas and Alliance Medical, Inc. Select Authentidate's Inscrybe Healthcare to Improve Care Order Processing 4Novel Technology in Treating Chronic Sinus Infections Available at Baptist 62107 1Novel Technology in Treating Chronic Sinus Infections Available at Baptist 62107 2Novel Technology in Treating Chronic Sinus Infections Available at Baptist 62107 3Its Official Work is Bad for Our Health 21 62105 1Its Official Work is Bad for Our Health 21 62105 2ChemoCentryx Reports Positive PROTECT 1 Study Results for Traficet EN 28TM 29 at the GASTRO 2009 UEGW WCOG Conference 6526 1ChemoCentryx Reports Positive PROTECT 1 Study Results for Traficet EN 28TM 29 at the GASTRO 2009 UEGW WCOG Conference 6526 2ChemoCentryx Reports Positive PROTECT 1 Study Results for Traficet EN 28TM 29 at the GASTRO 2009 UEGW WCOG Conference 6526 3ChemoCentryx Reports Positive PROTECT 1 Study Results for Traficet EN 28TM 29 at the GASTRO 2009 UEGW WCOG Conference 6526 4ChemoCentryx Reports Positive PROTECT 1 Study Results for Traficet EN 28TM 29 at the GASTRO 2009 UEGW WCOG Conference 6526 5
... Sept. 26 Threshold,Pharmaceuticals, Inc. (Nasdaq: THLD ... trial of glufosfamide plus gemcitabine were presented at ... Spain. In the Phase 2 clinical trial ... of advanced pancreatic cancer, six-month and,one-year survival were ...
... and BERLIN, Sept. 26 ,Genzyme Corporation (Nasdaq: ... announced that the first patient has been treated ... examining the safety and efficacy of alemtuzumab for,the ... I trial (Comparison of Alemtuzumab and Rebif Efficacy ...
Other Medicine Technology:Positive Glufosfamide Results From a Phase 2 Clinical Trial Presented at European Cancer Conference (ECCO) 2Positive Glufosfamide Results From a Phase 2 Clinical Trial Presented at European Cancer Conference (ECCO) 3Positive Glufosfamide Results From a Phase 2 Clinical Trial Presented at European Cancer Conference (ECCO) 4Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis 2Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis 3Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis 4Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis 5Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis 6
(Date:12/15/2009)... based on out-of-pocket costs for beneficiaries based on health status ... ... San Antonio, TX (Vocus) Dec. 14, 2009 -- Physicians ... to be recognized for cost-sharing effectiveness and value in the ... benefits for Medicare beneficiaries. The Medicare Advantage company won ...
(Date:12/15/2009)... that certain businesses with large areas where people gather, need ... Fire and rescue personnel agree that for any size business, ... , ... Issaquah, WA (PRWEB) December 15, ... certain businesses with large areas where people gather, need to ...
(Date:12/15/2009)... Dec. 15 issue of the Journal of Clinical ... increases the risk for developing obstructive sleep apnea (OSA) ... , Results indicate that the risk of OSA among ... 3.5 fold with each standard-deviation increase in body mass ... not significantly increase with increasing BMI among younger children. ...
(Date:12/14/2009)... Ill., Dec. 15 In today,s academic ... role than ever. Now the University HealthSystem Consortium ... Value Analysis: Achieving Cost Efficiencies in Health ... these complex environments. These new materials, developed with ... field, provide a practical guide to planning, implementing, ...
(Date:12/14/2009)... and HOLLYWOOD, Fla., Dec. 14 ... today a definitive agreement to acquire STARLIMS ... leading provider of laboratory information management systems, ... ,, The acquisition strengthens Abbott,s competitive position ... web-based applications to help laboratories efficiently store, ...
Breaking Medicine News(10 mins):Health News:Physicians Health Choice Receives Senior Choice Gold Award for 2010 Medicare Plan Benefits 2Health News:Physicians Health Choice Receives Senior Choice Gold Award for 2010 Medicare Plan Benefits 3Health News:Physicians Health Choice Receives Senior Choice Gold Award for 2010 Medicare Plan Benefits 4Health News:QuickMedical Responds to Oregon Bill Requiring Businesses to Carry Defibrillators 2Health News:QuickMedical Responds to Oregon Bill Requiring Businesses to Carry Defibrillators 3Health News:Obesity increases the risk for obstructive sleep apnea in adolescents, but not in younger children 2Health News:University HealthSystem Consortium Offers Value Analysis Professionals Insightful New Resources 2Health News:Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems 2Health News:Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems 3Health News:Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems 4
... from migraines avoid taking aerobic exercise because they are ... serious migraine attack. Researchers at the Sahlgrenska Academy, University ... that can improve fitness among migraine sufferers without aggravating ... are often advised to take exercise, but to date ...
... New research highlighting the relationship between steroids and ... post-liver transplant patients. This research will be ... Association of Clinical Endocrinologists (AACE) 18th Annual Meeting ... http://www.newscom.com/cgi-bin/prnh/20090324/DC88061LOGO-b )The tentative algorithm was ...
... leads health plans in member satisfaction in four ... Permanente announced today that its members in four ... in customer satisfaction in the J.D. Power and ... The regions are Colorado, Virginia-Maryland, California and the ...
... CMEF Booth #H1/F38 - Varian Medical Systems, Inc. (NYSE: ... flat panel digital X-ray image detectors will exhibit its line ... (DR) at the China International Medical Equipment Fair (CMEF) meeting ... will also showcase its full range of X-ray tubes for ...
... Mylan Inc. (Nasdaq: MYL ) today announced ... the company has declared its quarterly dividend of $16.25 per ... a liquidation preference of $1,000.00 per share) payable on May ... of May 1, 2009.Mylan Inc., which provides products to customers ...
... named Zultys as a recipient of the First Annual NGN Leadership Award ... ... April 15, 2009 -- Zultys Inc. announced today that ... the First Annual NGN Leadership Award for its outstanding contributions to IP ...
Other Medicine News:Health News:Safe exercise for migraine sufferers 2Health News:Treatment Algorithm Helps Successfully Manage Diabetes after Transplant Surgery 2Health News:Treatment Algorithm Helps Successfully Manage Diabetes after Transplant Surgery 3Health News:Kaiser Permanente Receives Top Marks in 2009 J.D. Power and Associates Study 2Health News:Kaiser Permanente Receives Top Marks in 2009 J.D. Power and Associates Study 3Health News:Kaiser Permanente Receives Top Marks in 2009 J.D. Power and Associates Study 4Health News:Varian Medical Systems to Exhibit the Latest X-Ray Image Detectors, and X-Ray Tubes at the CMEF Show in Shenzhen, China 2Health News:Zultys Inc. Receives 2009 NGN Leadership Award from NGN Magazine 2Health News:Zultys Inc. Receives 2009 NGN Leadership Award from NGN Magazine 3Health News:Zultys Inc. Receives 2009 NGN Leadership Award from NGN Magazine 4
... Durable ergonomic chairs with concave seats ... • Select options like seats, backrests, ... Choose the BE Series for top ... including: industry, education, laboratory, clean room, ...
... chairs with concave seats and large backrests ... seats, backrests, armrests, and casters and glides. ... performance in a variety of environments including: ... health care and office. • With cast ...
... chairs with concave seats and large ... options like seats, backrests, armrests, and ... BE Series for top performance in ... education, laboratory, clean room, static control, ...
... with concave seats and large backrests ... like seats, backrests, armrests, and casters ... Series for top performance in a ... laboratory, clean room, static control, health ...
Medicine Products: